clinical cases DDIs

Date of report 20 Nov 2020

Reported case interaction between **Raltegravir** and **Enzalutamide**

Drugs suspected to be involved in the DDI

Victim
Raltegravir

Daily Dose
1200 (mg)

Dose adjustment performed
No

Administration Route
Oral

Start date
Oct. 22, 2015

End date
Ongoing

Perpetrator
Enzalutamide

Daily Dose
160 (mg)

Dose adjustment performed
No

Administration Route
Oral

Start date
Feb. 5, 2016

End date
Ongoing

Complete list of drugs taken by the patient

Antiretroviral treatment

Abacavir/Lamivudine
Raltegravir

Complete list of all comedications taken by the patient, included that involved in the DDI

Enzalutamide 160mg OD Abiraterone 1g OD Amlodipine 10mg OD Metformin Rosuvastatin 20mg OD Travoprost eye drops

Clinical case description

Gender

Male

Age

73

eGFR (mL/min)

>60

Liver function impairment

No

Description

Patient was started on enzalutamide and abiraterone in Feb 2016 for prostate cancer. Patient was taking ABC/3TC/RAL 400mg BD at the time. Virological suppression was maintained throughout oncological treatment, including when the patient switched to RAL 1200mg OD in March 2018. The patient is currently still on enzalutamide and ABC/3TC/RAL 1200mg OD.

Clinical Outcome

No unwanted outcome

Editorial Comment

Enzalutamide is a strong CYP3A4 inducer and a moderate CYP2C9 and CYP2C19 inducer in humans. UGT1A1 may be induced as well. Although viral suppression was maintained in this case, close monitoring and maybe TDM and/or bid dosing of raltegravir might be considered in this scenario.

University of Liverpool Recommendation

■ Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration

For more information click here